Alar PharmaceuticalsROCO:6785 52 Current Ratio is 31.59 as of Dec. 2025, which is 29% below its 10-year median of 44.33. GuruFocus rates ROCO:6785 with a GF Score™ of 52/100 and a GF Value™ of NT$90.64 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,000 Drug Manufacturers companies, Alar Pharmaceuticals ranks better than 99% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Alar Pharmaceuticals's current ratio for the quarter that ended in Dec. 2025 was 31.59.
Alar Pharmaceuticals has a current ratio of 31.59. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Alar Pharmaceuticals's Current Ratio or its related term are showing as below:
ROCO:6785'
s Current Ratio Range Over the Past 10 Years
Min: 1.62 Med: 44.33 Max: 143.31
Current: 31.59
During the past 9 years, Alar Pharmaceuticals's highest Current Ratio was 143.31. The lowest was 1.62. And the median was 44.33.
ROCO:6785's Current Ratio is ranked better than 99% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs ROCO:6785: 31.59
Alar Pharmaceuticals (ROCO:6785) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Alar Pharmaceuticals Current Ratio Related Terms
Alar Pharmaceuticals Current Ratio Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alar Pharmaceuticals (ROCO:6785) has a Current Ratio of 31.59 as of Dec. 2025. This is 29% below median its historical median of 44.33. Over the past decade, Alar Pharmaceuticals' Current Ratio has ranged from 1.62 to 143.31. According to the industry distribution chart, Alar Pharmaceuticals ranks #10 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 1%.
Is Alar Pharmaceuticals' Current Ratio too high?
Alar Pharmaceuticals' current Current Ratio of 31.59 is 29% below median its 10-year median of 44.33. Over the past 10 years, this metric has ranged from a low of 1.62 to a high of 143.31. The Drug Manufacturers industry median Current Ratio is 2.00. Alar Pharmaceuticals' value of 31.59 is 1479.5% above this industry median. Based on the distribution chart, Alar Pharmaceuticals ranks #10 out of 1000 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alar Pharmaceuticals has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #10 out of 1000 companies for Current Ratio. This places Alar Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Alar Pharmaceuticals' value of 31.59 is 1479.5% above this benchmark. Historically, Alar Pharmaceuticals' own Current Ratio has ranged from 1.62 to 143.31 over the past decade. While the company's 10-year median is 44.33 vs. the industry median of 2.00, Alar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alar Pharmaceuticals's current Current Ratio of 31.59 is 1479.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alar Pharmaceuticals's current Current Ratio is 31.59, which is 29% below median its own 10-year median of 44.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$90.64, compared to a current price of NT$117.00 — trading 29.1% above its estimated fair value. The current Current Ratio is 31.59, which is 29% below median its 10-year median of 44.33 and 1479.5% above the Drug Manufacturers industry median of 2.00. Alar Pharmaceuticals' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Current Ratio is 31.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$117.00 is trading 29.1% above its estimated GF Value™ of NT$90.64.
GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ROCO:6785:
Current Ratio: 31.59 (29% below median its 10-year median of 44.33)
GF Value™: NT$90.64 vs. price of NT$117.00 (29.1% above fair value)
Industry Position: 1479.5% above the Drug Manufacturers median (#10 of 1000)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
52GF Score
Get the complete analysis for ROCO:6785
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
